AZN
USDAstraZeneca PLC American Depositary Shares
即時價格
價格圖表
關鍵指標
市場指標
開盤
$74.610
最高
$75.380
最低
$74.260
交易量
3.44M
公司基本面
市值
232.5B
行業
Drug Manufacturers - General
國家
United Kingdom
交易統計
平均交易量
5.47M
交易所
NMS
貨幣
USD
52週範圍
相關新聞
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes in the 1st-line
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark...
From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
Equity Insider News Commentary – The World Economic Forum recently spotlighted five healthcare breakthroughs, and at the top of the list was...
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in the New England Journal of Medicine and presented at ATS 2025
